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A major development in transfusion medicine during
the 1980s was the widespread use of autologous blood
for routine transfusion. In many situations, the use of
autologous blood transfusion became a standard of
care.1,2 In some states, laws dictate that the option of
autologous blood must be discussed with potential
blood recipients before elective surgery. Although some
blood bankers had for many years espoused, at least in
principle, the use of autologous blood, the real impetus
was the recognition of HIV as a threat to the safety of the
blood supply.2 An anxious public frequently has been
the standard bearer on this issue, serving as the catalyst
for change within the healthcare community.This pres-
sure resulted in a commitment to identify and deliver
alternatives to allogeneic blood transfusions. An addi-
tional impetus was the growing awareness by the clini-
cians and the public of other complications of transfu-
sion, specifically viral hepatitis.
As a consequence of these pressures, preoperative
autologous donations (PADs) increased dramatically
throughout the 1980s and into the 1990s.Years of expe-
rience with high-volume PADs and autologous blood
transfusion now enable us to analyze the risks as well as
the benefits and compare those with the risks and ben-
efits of allogeneic blood transfusion. The benefits of
PADs that are most frequently cited are elimination of
pathogenic viruses, reactions to foreign antigens, and
alloimmunization.
In 1982, there were 18,737 PADs, according to data
from the American Association of Blood Banks (AABB).
(It should be noted that these data are incomplete but
are the best available.) By 1991, this number had
increased to 745,000.3 However, since 1993 this num-
ber has declined. In a study of transfusion practice in
more than 150 New England hospitals, the New
England Region of the American Red Cross found that
autologous blood transfusions peaked in 1993 (28,862
total combined for the states of Massachusetts, Maine,
Vermont, and New Hampshire) and declined over the
subsequent 4 years to 23,180, a decrease of 17.8 per-
cent.
There are probably several reasons for the decline in
autologous blood donation and transfusions. The first
relates to the vastly increased safety of the blood supply.
With risks for HIV transmission at less than 1 per
600,000 units transfused and for viral hepatitis at less
than 1 in 100,000, it is likely that both clinicians and the
public have increased confidence in the safety of the
blood transfused. Recent public opinion surveys would
support this view. This has probably resulted in less
interest on the part of physicians and their patients in
PADs.Another factor is the high discard rate associated
with PADs,which results in high costs for hospitals.Data
collected by Popovsky and co-workers in Massachusetts
from that state’s 115 transfusion services shows that 48
percent of autologous blood collections were transfused
as either allogeneic blood or were discarded.4
Therefore, many autologous blood donations were
requested for surgical procedures for which there is 
little, if any, likelihood of transfusion. Examples of this
practice include PADs for routine hysterectomy, uncom-
plicated cholecystectomy, tubal ligation, and uncompli-
cated pregnancy. In the latter case, only 1–2 percent of
collected units are actually transfused to the mother.5
With increasing cost pressures on hospitals,blood banks
and hospital transfusion committees began to more sys-
tematically and objectively evaluate the need for autolo-
gous blood units. Using standard surgical blood orders
modified for autologous use, demand for autologous
blood units has diminished.6
Cost Effectiveness
A series of studies examining the cost-effectiveness of
PADs have been published recently. Etchason and col-
leagues used a decision analysis model to assess the
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effectiveness of PADs.7 Their data were based on 1992
transfusion practices in southern California. Their mea-
sure of weighing effectiveness was dollars per quality
adjusted life year (QALY). For most accepted medical
surgical interventions, the QALY is less than $50,000.
These investigators evaluated four surgical procedures:
total hip replacement, coronary artery bypass graft
(CABG), hysterectomy, and transurethral prostatectomy
(TURP).They found that PAD was associated with addi-
tional per unit costs that ranged from $68 for total hip
replacement to $4,783 for TURP. Even more impressive
were the calculations for the dollars per QALY, which
ranged from $235,000 for total hip replacement, to
$494,000 for CABG, to $1,358,000 for abdominal hys-
terectomy.The authors concluded that autologous blood
transfusion was not justified by the cost. Because the
authors based their analysis on transfusion risk estimates
of 1 per 150,000 for HIV and 1992 transfusion practices,
these findings would be even more striking (less cost
effective) if 1997 data were used. Since 1992, clinicians
have accepted greater levels of anemia before transfus-
ing their patients.
Birkmeyer et al.8 conducted a second study that used
decision analysis.Again,dollars per QALY were used as a
measure of cost effectiveness.These authors found that
for both CABG and orthopedic surgery procedures, the
cost effectiveness was directly linked to the likelihood of
transfusion. Thus, with bilateral hip or revision arthro-
plasty, the cost per QALY was $40,241.For unilateral hip
arthroplasty, they calculated the cost per QALY between
$373,000 and $740,000.Thus, PAD was seen as a cost-
ineffective transfusion modality.
Not all investigators share this view. Another group
has drawn contradictory conclusions. Blumberg and co-
workers compared the cost consequences of autologous
and allogeneic blood transfusions.9 They evaluated the
incremental hospital costs per unit transfused in hip
replacement surgery.The authors found that for donors
of autologous blood,the mean total charges were $7,200
more for recipients of both autologous and allogeneic
blood transfusions compared with recipients of autolo-
gous transfusion only (p = .0001). In a cohort of patients
receiving identical amounts of either allogeneic or autol-
ogous blood, total hospital charges were a mean of
$4,500 greater for allogeneic recipients (p = .0001). The
authors concluded that allogeneic transfusions were
associated with incremental hospital costs of $1,000–
$1,500 per unit transfused when compared with costs
for similar patients receiving no transfusions or 1–5
autologous blood units. It is important to note that the
contradictory conclusion about the economic benefit of
PADs is based on a cost, rather than cost-effectiveness,
analysis.
Despite the cost pressures on hospitals,many patients
remain willing to pay additional out-of-pocket charges to
obtain PAD services. In a recent study, Lee et al.10 found
that despite education about the low risk of allogeneic
blood transfusion,the dread of allogeneic blood and will-
ingness to pay for PADs are substantial. In a survey of
647 patients making PADs, these authors found the
median population willingness to pay for PADs correlat-
ed with their level of dread,perceived risk of requiring a
blood transfusion, and income level (p < .05). Many
patients were willing to pay as much as $1,200–$1,900
for PADs.This study suggests that despite decreasing risk
to the allogeneic blood supply, unfavorable cost-effec-
tiveness studies, and pressures to reduce costs in the
healthcare system, PADs will remain an important trans-
fusion option into the foreseeable future.
Adverse Outcomes
Throughout the 1980s and into the early 1990s,
numerous studies examined the questions of safety of
PADs. These studies evaluated the incidence of donor
reactions, emphasizing medically high-risk donors (e.g.,
those with cardiovascular disease). These studies con-
cluded that PAD is not significantly less safe than blood
donation in the healthy population. These conclusions
also applied to the so-called high-risk donor. In one
study, the authors found that the antecedent medical his-
tory (including a history of cardiovascular disease) was a
poor predictor of reactions.11 A limitation of all these
studies are that they are retrospective, uncontrolled, and
involve relatively small populations for analysis.
However, one uncontrolled study demonstrated
potentially significant hemodynamic changes in patients
and donors with a history of cardiovascular disease. In a
study of 123 patients with major cardiovascular disease
in which there was close monitoring of blood pressure,
heart rate,cardiac output, lead II cardiography,and pulse
oxymetry, Speiss et al.12 found systolic and diastolic
hypotension, orthostatic hypotension, and arrhythmias
(including premature ventricular contractions). These
changes were seen in 3.1–22 percent of the patients.
Because of the lack of controls or other types of autolo-
gous blood donors, these data are difficult to interpret.
Using a large, recently developed data base, Popovsky
and colleagues examined the occurrence of very severe
outcomes (VSOs) in patients undergoing PAD.13 The
authors defined a VSO as one requiring hospitalization.
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Evaluating more than 4 million donations in 1993–1994,
the authors found that the rate for a VSO in an autolo-
gous blood donor was 12 times that seen in allogeneic
blood donors.The incidence of VSO in autologous blood
donors was 1 per 16,783 donations versus 1 per 198,119
(p <  .001).The most common VSOs were angina (66.7%
of all VSOs) and tetany (12.1%). Contrary to previous
studies that suggested that there are fewer donor reac-
tions in older donors, these investigators found that
VSOs were most likely in donors younger than 60 years
of age. Eleven of 13 VSOs occurred in such donors.The
mean hospital stay was 1.9 days.The authors concluded
that the VSO is an infrequent complication of all types of
blood donation, but its occurrence may be associated
with significant morbidity and cost. In Germany,
Singbartl et al.14 studied 28,000 orthopedic patients
making 132,093 PADs. Using three-lead ECG and nonin-
vasive blood pressure monitoring,as well as replacement
therapy by crystalloids or colloids, these authors investi-
gated adverse events (AEs).They found that severe AEs
were observed in 1 per 9,414 patients (0.011%) or 1 in
44,000 units of blood donated. Fatal events occurred in
1 in 14,122 patients (1 in 66,000 autologous blood units
donated). The fatal events observed were pulmonary
embolism and severe asthma attack.These authors con-
cluded that PADs may be associated with serious risk,
but it was difficult to conclude that these risks were pre-
cipitated by the autologous blood donations.These data
support the findings of the American Red Cross Study.13
On balance, these studies support the conclusion of ear-
lier studies regarding the overall safety of PADs, but they
underscore the fact that AEs may occur.
Another underexplored topic is adverse transfusion
reactions to autologous blood. Autologous therapy is the
safest form of transfusion; therefore, transfusion reac-
tions involving an immune response are not to be
expected. A recent study by Domen found that 15 of 967
transfusion reactions (1.6%) at a large teaching hospital
were associated with PADs.15 He found that 25 percent
of these reactions were of the febrile,nonhemolytic type
and another 20 percent were allergic. Most significant
was the occurrence of an acute hemolytic reaction due
to an ABO mismatch.The author concluded that transfu-
sion reactions are associated with autologous blood, that
they can be severe, and that all such reactions must be
investigated.
Management of Autologous Blood Donation
Once an autologous blood donation is collected, a
complex system of logistics is called into play to ensure
that the unit arrives safely at the patient’s bedside or in
the operating room at the time it is needed. A recent
Canadian study suggests that these logistics are not
always well managed. Using a detailed questionnaire
that was sent to 31 hospitals served by the Canadian
Red Cross of Quebec, Goldman and colleagues studied
deviation reports and calculated error rates.16 They
found that 113 errors occurred for 16,783 units collect-
ed, for a disturbingly high rate of 1 in 149 units collect-
ed. In their analysis of the errors, they found that 10 per-
cent were associated with allogeneic blood units being
transfused instead of autologous blood units;25 percent
were units arriving late for surgery; 23 percent were
units sent to the wrong hospital; 13 percent had label-
ing problems; and 7 percent were involved with trans-
portation or storage problems.These authors concluded
that errors are not an infrequent event with autologous
blood donations.
These data are corroborated by a 1992 College of
American Pathologists survey that found that 34 of 3,852
institutions (0.8%) reported one or more instances of
issuing an autologous blood unit to the wrong patient.17
A 1995 AABB survey indicated that 22 of 1,829 respon-
dents (1.2%) reported an erroneous transfusion of one
or more autologous blood units to someone other than
the intended recipient.18 These data underscore the lack
of fail-safe systems associated with the procurement and
transfusion of autologous blood units.
In conclusion, autologous blood transfusion remains
an important part of perioperative hemotherapy. It
appears that its usage is diminishing as a result of a vari-
ety of factors.For the vast majority of patients or donors,
PAD is safe. However, severe reactions and outcomes
may result from the donation. Because systems involved
in the procurement and distribution of PADs are com-
plex and often cumbersome, errors can and do occur.
Finally, it would appear that some autologous blood units
are associated with a reaction in the intended recipient.
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